In HER2+ BC, HER2 induced expression of IL-1α and IL-6, which then increased drug-resistance-related CSCs in primary tumor, while blocking IL-1 signaling increased the efficacy of chemotherapy when combined with cisplatin and paclitaxel [87]. Here, ERBB2 is linked to neoplasm.